Genaera — Technical Presentation (August 2007)
37 slides from Genaera's technical presentation, Aug 9, 2007
Slide 1: Trodusquemine - A Novel Aminosterol for the Treatment of Obesity
Trodusquemine - A Novel Aminosterol for the Treatment of Obesity and Related Metabolic Disorders Case Studies: Moving a Compound from Discovery to Preclinical to Proof-of-Concept Boston, MA August 8, 2007 Anthony DelConte, MD Vice President, Clinical R & D Exhibit 99.2
Slide 2: Trodusquemine (MSI-1436)
Trodusquemine (MSI-1436) N H N H N H O H OH S O OH O N H
Slide 3: Obesity Comorbidities
Pulmonary disease Pulmonary disease abnormal function abnormal function obstructive sleep apnea obstructive sleep apnea hypoventilation syndrome hypoventilation syndrome Nonalcoholic fatty liver Nonalcoholic fatty liver disease disease steatosis steatosis steatohepatitis steatohepatitis cirrhosis ci
Slide 4: Unmet Medical Needs - Obesity
Unmet Medical Needs - Obesity • Current Therapies (US) – Phentermine – short term – Sibutramine – Orlistat – Rimonobant (withdrawn after June 13 FDA mtg) • Over 300 Drugs in Development – 42 Phase I-III 38 different MOAs (12% DA, 8% CB1) Source: Datamonitor 2006
Slide 5: History of Trodusquemine Development
History of Trodusquemine Development • Aminosterol ( Squalus acanthias ) – Fully synthetic process • Animals Experience Weight Loss • Serendipity • Development as an Obesity Therapy
Slide 6: (SGENAERA
(SGENAERA
Slide 7: Inhibitor Specificity Difficult Due to High Homology Between PTP-1B and TC-PTP
Inhibitor Specificity Difficult Due to High Homology Between PTP-1B and TC-PTP Iversen, L. F. et al. J. Biol. Chem. 2002;277:19982-19990 PTP-1B TC-PTP
Slide 8: A Selective PTP-1B Inhibitor
A Selective PTP-1B Inhibitor MSI-1436 is highly selective for PTP-1B relative to TC - PTP -8 -7 -6 -5 -4 -3 -2 PTP1B TCPTP MSI-1436 log (M) 224 µM TC-PTP 1 µM PTP-1B IC Enzyme 224 µM TC-PTP 1 µM PTP-1B IC Enzyme
Slide 9: MSI-1436 is an Allosteric, Noncompetitive Inhibitor of PTP-1B
MSI-1436 is an Allosteric, Noncompetitive Inhibitor of PTP-1B 149.33 7.60 425.34 36.40 V max uM pNP/min/ug of protein 3.63 0.30 pNPP + MSI 1436 2.25 0.40 pNPP K m (mM) Experiment 149.33 7.60 425.34 36.40 V max uM pNP/min/ug of protein 3.63 0.30 pNPP + MSI 1436 2.25 0.40 pNPP K m (mM) Experiment pNPP
Slide 10: MSI-1436 Inhibits PTP-1B in Cell Based Assay
30 minutes 3 hours IR IR IP, P-Tyr IR IR IP, P-Tyr HepG2 cells MSI-1436 Inhibits PTP-1B in Cell Based Assay X X X X Trodusquemine X X X X Insulin X X X X Trodusquemine X X X X Insulin 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 Trodusquemine Induces IR Phosphorylation
Slide 11: PTP-1B Target Validation
Body Wt Appetite Fatty Acid Oxidation Leptin Sensitivity Insulin Sensitivity 1436 (DIO mice) Brain-Specific KO Brain-specific PTP-1B Knock-Out mimics MSI-1436 induced weight loss PTP-1B Target Validation Bence, et al, Nature Med, 12(8): 917-924 (2006) Central Effect - Obesity Body Wt Appetite Fatty
Slide 12: MSI-1436 Induces Central c-fos Activity
MSI-1436 Induces Central c-fos Activity R. Ahima et al, Diabetes , 51:2099-2014, 2002 Vehicle MSI-1436 c-fos indicates neural activity
Slide 13: Establishing Preclinical Efficacy
Establishing Preclinical Efficacy
Slide 14: MSI-1436 Induced Weight Loss in Multiple Obesity Models
• ob/ob mouse • db/db mouse • Diet-induced obese (DIO) mouse • Zucker fa/fa rat MSI-1436 Induced Weight Loss in Multiple Obesity Models:
Slide 15: MSI-1436 Induced Weight Loss
MSI-1436 Induced Weight Loss -80 -60 -40 -20 Day of Study Vehicle MSI-1436 (5 mg/kg) (ob/ob Mouse Model) 151% - 61%
Slide 16: MSI-1436 in DIO Model
Control Diet 60% Fat Diet MSI-1436 in DIO Model Dosing Schedule Day 0 - 10 mg/kg Day 7 - 5 mg/kg Day 14 – 5 mg/kg Day 21 – 5 mg/kg • Proportional to pre-treatment body weight • Weight lost is all fat • No muscle loss Treatment Period Fattening Period 14% 37% 41% Weight Loss 45% Fat Diet Time (Days)
Slide 17: MSI-1436 Impact on Adipose
White Adipose Tissue Brown Adipose Tissue 60% fat diet, Saline 60% fat diet, Trodusquemine MSI-1436 Impact on Adipose Dramatic, Visual Decrease in Stored Fat
Slide 18: MSI-1436 and Rebound
MSI-1436 and Rebound -50 -40 -30 -20 -10 Study Day 60% diet, Trodusquemine 60% diet, Pair-fed Resists Change in Metabolic Set Point
Slide 19: MSI-1436 and Type 2 Diabetes
MSI-1436 and Type 2 Diabetes Takahashi, et al, J. Hepatology, 41: 391-398 (2004) Improves Insulin Sensitivity (Independent of weight loss) Saline Pair-Fed MSI-1436 Wild type mice Lowers Blood Glucose Single 1436 dose at t-1 day Insulin bolus at t = 0 Ob/Ob mice Multiple 1436 doses 8 mg/kg (q4 days x
Slide 20: MSI-1436 and Dyslipidemia
MSI-1436 and Dyslipidemia Lowers Serum Cholesterol Lowers Serum Triglycerides 95.4 78.2 Ob/Ob Pair-fed Ob/Ob Saline Ob/Ob MSI-1436 Wild-type saline 0.1 0.31 3.1 MSI-1436, mg/kg/week M. Zasloff et al Intl J Obesity 25: 689-697, 2001
Slide 21: Establish Preclinical Safety: Toxicology
Establish Preclinical Safety Toxicology
Slide 22: MSI-1436 (Trodusquemine) Completed Studies by Type
MSI-1436 (Trodusquemine) MSI-1436 (Trodusquemine) Completed Studies by Type Completed Studies by Type • • Genetic Toxicity : Genetic Toxicity : Bacterial mutation (Ames Bacterial mutation (Ames test), in vitro test), in vitro (CHO) and in vivo (CHO) and in vivo (mouse (mouse micronucleus) chromosoma
Slide 23: First-in-Human
First-in-Human IND Filed March 2007 First Subject Dosed May 17th
Slide 24: Phase I Study Overview
Phase I Study Overview • To evaluate the safety and tolerance of ascending single IV doses of MSI-1436 • To evaluate pharmacokinetics (PK) of MSI-1436 • Healthy overweight or obese male and female subjects – 18 to 55 years of age – BMI of 27-40 kg/m2
Slide 25: MSI-1436 Study Design
MSI-1436 101 Study Design • Double blind, randomized, placebo- controlled • 7 subjects per group enrolled in sequential dose groups • 5 subjects receive MSI-1436 and 2 subjects receive vehicle in each dose group
Slide 26: Study Design
Study Design • 3 week screening • Admitted on Day –1 and to remain in house for 4 nights • Return on Days 7,14, & 21 for follow-up • Vital signs • Clinical laboratories • PK sample collections • Day 21, all end-of-study evaluations
Slide 27: Inclusion/Exclusion Criteria
Inclusion/Exclusion Criteria • Inclusion – Healthy male or female subjects, between 18 and 55 years old – Non-smokers - (Cotinine levels <200 ng/mL) – BMI of 27- 40 kg/m • Exclusion – Clinically significant disease history – Abnormal vital signs, PE, labs, or any safety variable – Requires treatment
Slide 28: Pharmacokinetics of MSI-1436
Pharmacokinetics of MSI-1436 Time (hours) Cohort (0.3 mg/m ) Cohort (1 mg/m ) Cohort (3 mg/m ) Cohort (10 mg/m )
Slide 29: AUC (inf)
AUC{inf) (ug*himL) 28) 100 10 a4 0.01 ° Individual Mean - Median 1 1 Dose {mgim”) 10 ©'GENAERA
Slide 30: Cmax
Cmax (ug/mL) a4 o.01 30 i} Individual Mean Median a4 1 Dose (mgim’) 10 ©'GENAERA
Slide 31: Adverse Events (Drug & Vehicle)
Adverse Events (Drug & Vehicle) • No Serious AEs Reported • 19 Subjects reported 44 AEs – 38 grade 1 – 6 grade 2 • 9 subjects had no AEs • 23 occurred within 24 hours of dosing • 16 occurred 2 or more days after dosing
Slide 32: Adverse Events
Adverse Events • There were no discontinuations due to AEs • No safety signals, profile consistent with placebo (vehicle) • Plan to continue until dose limiting toxicity is established
Slide 33: Conclusions
Conclusions • Trodusquemine is a centrally acting, selective PTP-1B inhibitor in Phase I development • Preclinical efficacy has been demonstrated in multiple diet induced and transgenic models of obesity • Although pursued for over a decade, PTP-1B as a target has defied rational drug design strateg
Slide 34: Back-up Slides
Back-up Slides
Slide 35: (GENAERA
(GENAERA
Slide 36: (GENAERA
(GENAERA
Slide 37: MSI-1436 Reduces Body Fat in DIO Mouse Model
Vehicle MSI-1436 Vehicle MSI-1436 Vehicle MSI-1436 MSI-1436 Reduces Body Fat 10% Fat Diet 60% Fat Diet 45% Fat Diet p < 0.001 p < 0.001 p < 0.001 in DIO Mouse Model